Gastrodin and AT1 Blockade Shape Astrocyte Reactivity via RAS–SIRT3 Axis

Study Background and Research Question

The central nervous system (CNS) relies on tightly regulated interactions between glial cells to maintain homeostasis and respond to injury or disease. Microglia, as resident immune cells, initiate inflammatory responses, while astrocytes contribute to tissue repair, blood-brain barrier maintenance, and modulation of synaptic activity. Recent research has revealed that astrocytes can adopt distinct reactive phenotypes—proinflammatory A1 and neuroprotective A2—which are shaped by microglia-derived signals and molecular pathways such as the renin-angiotensin system (RAS). The reference study aimed to elucidate how gastrodin—a phenolic glycoside known for anti-inflammatory and neuroprotective properties—and angiotensin II type 1 (AT1) receptor blockade regulate RAS–SIRT3 signaling and the phenotypic transformation of astrocytes via microglial activation.

Key Innovation from the Reference Study

The key innovation of this work lies in its integrated approach to dissecting the interplay between microglia and astrocytes in neuroinflammation. The authors systematically demonstrated that gastrodin modulates the expression of RAS components (including angiotensinogen, ACE, and AT1/AT2 receptors) and SIRT3—a mitochondrial deacetylase associated with cellular stress responses—in reactive astrocytes. Moreover, by employing a selective AT1 receptor antagonist (Azilsartan/TAK-536), the study provides mechanistic evidence that AT1 blockade influences the phenotypic marker expression of reactive astrocytes. This dual modulation of both inflammatory mediators and neurotrophic factors through the RAS–SIRT3 axis constitutes a significant advance in understanding glial cell interactions during CNS inflammation.

Methods and Experimental Design Insights

The experimental design leveraged a co-culture-like system involving TNC-1 astrocytes and BV-2 microglia. BV-2 cells were treated with lipopolysaccharide (LPS) to induce activation, and their conditioned medium (CM) was used to stimulate TNC-1 astrocytes. Gastrodin was applied to investigate its effect on microglia-mediated astrocyte reactivity. Key molecular endpoints included the expression of RAS pathway components (ATO, ACE, AT1, AT2), SIRT3, astrocyte phenotype markers (C3 for A1, S100A10 for A2), proinflammatory cytokines (e.g., IL-1β, TNF-α), and neurotrophic factors (IGF-1, BDNF). Quantitative RT-PCR, immunofluorescence, and western blotting provided complementary measures of mRNA and protein expression. The study also introduced Azilsartan to selectively inhibit AT1 and probe its downstream effects on astrocyte reactivity.

Protocol Parameters

• BV-2 microglia activation: 1 μg/mL LPS for 24 h to stimulate proinflammatory signaling.
• Conditioned medium preparation: Collect BV-2 supernatant after LPS (or LPS + gastrodin) treatment for use with TNC-1 astrocytes.
• Gastrodin application: 100 μM co-applied with LPS in microglial cultures, prior to collection of conditioned medium.
• Azilsartan (TAK-536) use: 10 μM added to astrocyte cultures during exposure to microglia CM to selectively inhibit AT1 receptor signaling.
• Readouts: Assess mRNA (RT-PCR) and protein (immunofluorescence, western blot) for RAS components, SIRT3, phenotype markers (C3, S100A10), cytokines, and neurotrophic factors after 24 h.

Core Findings and Why They Matter

Exposure of TNC-1 astrocytes to LPS-activated microglia CM significantly increased expression of RAS pathway genes (ATO, ACE, AT1), SIRT3, proinflammatory markers (C3, cytokines), and neurotrophic factors, while reducing AT2 and S100A10 (A2 marker) expression. When microglia were pre-treated with gastrodin, these changes were reversed: the expression of proinflammatory and RAS components decreased, whereas SIRT3, IGF-1, and BDNF increased, indicating a shift toward a neuroprotective profile. Notably, application of Azilsartan (TAK-536) to astrocyte cultures recapitulated aspects of this shift, confirming that AT1 receptor activity is a key regulatory node in this pathway. Thus, the study demonstrates that both gastrodin and pharmacological AT1 blockade can mitigate astrocyte-mediated neuroinflammation by modulating RAS–SIRT3 signaling (reference study).

These findings have practical implications for researchers studying the pathophysiology of neuroinflammatory diseases, as the RAS–SIRT3 axis and AT1 signaling are increasingly recognized as therapeutic and mechanistic targets. The demonstration that Azilsartan—a potent and selective AT1 receptor inverse agonist—can precisely modulate astrocyte phenotype supports its utility in dissecting the cellular mechanisms of neuroinflammation.

Comparison with Existing Internal Articles

The reference study’s mechanistic insights are consistent with and extend recent literature. For example, internal reviews highlight how AT1 receptor antagonism, including with Azilsartan, modulates astrocyte reactivity and RAS–SIRT3 signaling. Similarly, other summaries emphasize the dual role of gastrodin and AT1 blockade in controlling both inflammation and neurotrophic support in astrocyte–microglia models. Notably, recent applications of Azilsartan in cardiovascular and neuroinflammatory research underscore its reproducibility and specificity for AT1 in vitro, aligning with the current study’s observations.

Limitations and Transferability

While the study offers robust mechanistic insights, several limitations warrant consideration. The use of immortalized cell lines (BV-2 microglia, TNC-1 astrocytes) may not fully recapitulate the complexity of primary glial responses or in vivo CNS environments. The focus on acute inflammatory signaling may not capture long-term or disease-specific changes in RAS–SIRT3 dynamics. Additionally, while Azilsartan was effective in this model, dose-responsiveness and potential off-target effects in primary cells or animal models require further clarification. Transferability to models of chronic neurodegeneration or human glial cell systems should be approached cautiously until corroborated by additional studies.

Research Support Resources

For researchers aiming to replicate or extend these findings, high-purity AT1 antagonists are essential. Azilsartan (TAK-536, SKU B2210) from APExBIO is a well-characterized, potent AT1 inverse agonist (IC₅₀ 2.6 nM) that is widely used in studies of the renin-angiotensin system, cardiovascular, and neuroinflammatory models. Its solubility profile (≥16.95 mg/mL in DMSO) and validated purity make it suitable for cell-based assays examining the role of AT1 signaling in reactive astrocytes and microglia. Researchers may refer to the internal protocols for best practices in inhibitor handling and workflow optimization. Combining gastrodin, selective AT1 antagonists, and robust molecular assays provides a powerful approach for dissecting glial cell interactions in neuroinflammation.